SCHEMBL177280

SCHEMBL177280

CC(C)OC(=O)c1cccc(B(O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
HTT P42858 2/20 0.54
MAPT P10636 2/20 0.54
CA12 O43570 4/20 0.51
CA1 P00915 4/20 0.51
CA2 P00918 4/20 0.51
CA7 P43166 4/20 0.51
CA9 Q16790 4/20 0.51
CA14 Q9ULX7 4/20 0.51
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
PDCD1 Q15116 1/20 0.47
CD274 Q9NZQ7 1/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.45
ENPP2 Q13822 2/20 0.43
JMJD6 Q6NYC1 1/20 0.43
CYP4F2 P78329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31483553 1.00 NPC1 (0.54) NPC1RAB9ASMN1; SMN2HTTMAPT
SCHEMBL43683 0.84 NPC1 (0.65) NPC1RAB9ASMN1; SMN2HTTMAPT
SCHEMBL257629 0.81 CA1 (0.49) NPC1RAB9ASMN1; SMN2HTTMAPT
SCHEMBL20989 0.81 TSHR (0.53) NPC1RAB9ASMN1; SMN2CA12CA1
SCHEMBL1586281 0.80 ALDH1A1 (0.50) ALDH1A1ENPP2JMJD6
Methyl Alcohol SCHEMBL28708861 0.79 TSHR (0.52) NPC1RAB9ASMN1; SMN2CA12CA1
SCHEMBL30678282 0.79 NPC1 (0.56) NPC1RAB9ASMN1; SMN2HTTMAPT
SCHEMBL8759589 0.79 NPC1 (0.56) NPC1RAB9ASMN1; SMN2HTTMAPT
SCHEMBL141580 0.79 CA12 (0.63) NPC1RAB9ASMN1; SMN2HTTMAPT
SCHEMBL15981536 0.77 KDM4E (0.47) ALDH1A1ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024191268-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 현대약품 주식회사 2024-09-19 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 US disclosed
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 EP disclosed
US-9718809-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2017-08-01 US disclosed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 US disclosed
US-20150344503-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME INFINITY PHARMACEUTICALS INC (US) 2015-12-03 US disclosed
US-9108989-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-08-18 US disclosed
US-9012651-B2 TRPV3 modulators ABBVIE INC. (US) 2015-04-21 US disclosed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 US disclosed
US-20080176678-A1 Compositions for Use in Golf Balls ACUSHNET COMPANY 2008-07-24 US disclosed
WO-2008063300-A2 BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed
US-7361711-B2 Compositions for use in golf balls ACUSHNET COMPANY (US) 2008-04-22 US disclosed
US-7358310-B2 Compositions for use in golf balls ACUSHNET COMPANY (US) 2008-04-15 US disclosed
US-7358309-B2 core or the layer includes a composition formed from a base polymer, a crosslink initiator, and at least one additive; additive has at least one carbon-oxygen-boron linkage, carbon in the linkage being a secondary or tertiary carbon; enhances coefficient of restitution and/or reduces compression of core ACUSHNET COMPANY (US) 2008-04-15 US disclosed
US-7358308-B2 Compositions for use in golf balls ACUSHNET COMPANY (US) 2008-04-15 US disclosed
US-20060281586-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2006-12-14 US disclosed
US-20060281587-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2006-12-14 US disclosed
US-20050245652-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2005-11-03 US disclosed
US-20050245657-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF NPC1 1526/4885RAB9A 1664/4885SMN1; SMN2 3575/4885
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF NPC1 1593/4885RAB9A 1800/4885SMN1; SMN2 3612/4885
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer NFKBIA, IL6, LITAF NPC1 1593/4885RAB9A 1800/4885SMN1; SMN2 3612/4885
US-20150344503-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME FAAH, FAAH2, ASAH1 NPC1 483/4885RAB9A 1762/4885SMN1; SMN2 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.